Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CDR0000269314 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy in different ways may cause less damage to normal tissue, prevent or lessen mouth dryness, and may help patients live more comfortably. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of specialized radiation therapy techniques with or without chemotherapy in reducing mouth dryness in patients who have nasopharyngeal cancer.
OBJECTIVES:
OUTLINE: Patients undergo daily intensity-modulated radiotherapy (IMRT) 5 days a week for approximately 6.5 weeks (total of 33 fractions) in the absence of disease progression or unacceptable toxicity.
Patients with stage T2b or greater and/or node-positive disease receive cisplatin IV over 20-30 minutes on days 1, 22, and 43 concurrently with IMRT followed by cisplatin IV over 20-30 minutes and fluorouracil IV over 96 hours starting on days 71, 99, and 127.
Quality of life is assessed through saliva measurement at baseline and then at 3, 6, and 12 months after IMRT.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 64 patients will be accrued for this study within 36-40 months.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| IMRT +/- chemotherapy | Experimental | Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+ |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| cisplatin | Drug | 100 mg/m^2 intravenously on days 1, 22, and 43 and 80 mg/m^2 intravenously on days 71, 99, and 127 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Protocol Compliance of Intensity-modulated Radiotherapy Treatment Delivered | Patients scored by the study chairs as no variation or minor variation were considered compliant, while patients scored as major variation or inevaluable were considered non-compliant. The number being reported is the number non-compliant. A compliance rate of 90% was targeted with 75% or lower being considered unacceptable. Fifty-seven patients were required with types I and II error rates both 0.10. If 10 or more patients out of 57 were non-compliant, the treatment would be unacceptable, per a two-stage Fleming multiple testing procedure. | From start of treatment to end of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of Xerostomia at 1 Year (Grade ≥ 2) | From start of treatment to 1 year | |
| Rate of Locoregional Control at 2 Years | From registration to 2 years | |
| Whole Mouth Saliva Output Relative to Pretreatment Measurements |
Not provided
DISEASE CHARACTERISTICS:
Histologically confirmed stage I-IVB squamous cell carcinoma of the nasopharynx
Measurable or evaluable disease
Must have been treated with primary radiotherapy
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nancy Lee, MD | Memorial Sloan Kettering Cancer Center | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Comprehensive Cancer Center at University of Alabama at Birmingham | Birmingham | Alabama | 35294 | United States | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20441239 | Result | Chen A, Lee N, Yang C, Liu T, Narayan S, Vijayakumar S, Purdy J. Comparison of intensity-modulated radiotherapy using helical tomotherapy and segmental multileaf collimator-based techniques for nasopharyngeal carcinoma: dosimetric analysis incorporating quality assurance guidelines from RTOG 0225. Technol Cancer Res Treat. 2010 Jun;9(3):291-8. doi: 10.1177/153303461000900308. | |
| 19564532 |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | IMRT +/- Chemotherapy | Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+ |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| fluorouracil | Drug | 1000 mg/m^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130 |
|
| Intensity modulated radiation therapy | Radiation | The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume [CTV] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days. |
|
| From start of treatment to 1 year |
| Other Acute and Late Toxicities | From start of treatment to last follow-up |
| Chemotherapy Compliance | From start of treatment to end of treatment |
| University of California Davis Cancer Center |
| Davis |
| California |
| 95616 |
| United States |
| Radiological Associates of Sacramento Medical Group, Incorporated | Sacramento | California | 95815 | United States |
| UCSF Comprehensive Cancer Center | San Francisco | California | 94115 | United States |
| Northeast Georgia Medical Center | Gainesville | Georgia | 30501 | United States |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | United States |
| Siteman Cancer Center at Barnes-Jewish Hospital | St Louis | Missouri | 63110 | United States |
| Monmouth Medical Center | Long Branch | New Jersey | 07740 | United States |
| Albuquerque Regional Medical Center at Lovelace Sandia Health System | Albuquerque | New Mexico | 87102 | United States |
| Akron City Hospital | Akron | Ohio | 44304 | United States |
| Kimmel Cancer Center at Thomas Jefferson University - Philadelphia | Philadelphia | Pennsylvania | 19107 | United States |
| Fox Chase-Temple Cancer Center | Philadelphia | Pennsylvania | 19111-2497 | United States |
| CCOP - MainLine Health | Wynnewood | Pennsylvania | 19096 | United States |
| M.D. Anderson Cancer Center at University of Texas | Houston | Texas | 77030 | United States |
| Wilford Hall Medical Center | Lackland Air Force Base | Texas | 78236 | United States |
| McKay-Dee Hospital Center | Ogden | Utah | 84403 | United States |
| Medical College of Wisconsin Cancer Center | Milwaukee | Wisconsin | 53226 | United States |
| Result |
| Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, Jones C, Ang KK. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009 Aug 1;27(22):3684-90. doi: 10.1200/JCO.2008.19.9109. Epub 2009 Jun 29. |
| Result | Lee NY, Harris J, Garden A, et al.: Phase II multi-institutional study of IMRT ± chemotherapy for nasopharyngeal carcinoma (RTOG 0225): preliminary results. [Abstract] Int J Radiat Oncol Biol Phys 69 (3 Suppl): A-23, S13-14, 2007. |
| COMPLETED |
|
| NOT COMPLETED |
|
All eligible patients
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | IMRT +/- Chemotherapy | Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+ |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median | Full Range | years |
| |||||||||||||||||
| Gender | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Protocol Compliance of Intensity-modulated Radiotherapy Treatment Delivered | Patients scored by the study chairs as no variation or minor variation were considered compliant, while patients scored as major variation or inevaluable were considered non-compliant. The number being reported is the number non-compliant. A compliance rate of 90% was targeted with 75% or lower being considered unacceptable. Fifty-seven patients were required with types I and II error rates both 0.10. If 10 or more patients out of 57 were non-compliant, the treatment would be unacceptable, per a two-stage Fleming multiple testing procedure. | First 57 eligible patients who started study treatment. | Posted | Number | participants | From start of treatment to end of treatment |
|
|
| ||||||||||||||||||||||||||
| Secondary | Rate of Xerostomia at 1 Year (Grade ≥ 2) | Not Posted | From start of treatment to 1 year | Participants | ||||||||||||||||||||||||||||||||
| Secondary | Rate of Locoregional Control at 2 Years | Not Posted | From registration to 2 years | Participants | ||||||||||||||||||||||||||||||||
| Secondary | Whole Mouth Saliva Output Relative to Pretreatment Measurements | Not Posted | From start of treatment to 1 year | Participants | ||||||||||||||||||||||||||||||||
| Secondary | Other Acute and Late Toxicities | Not Posted | From start of treatment to last follow-up | Participants | ||||||||||||||||||||||||||||||||
| Secondary | Chemotherapy Compliance | Not Posted | From start of treatment to end of treatment | Participants |
Not provided
Subjects experiencing more than one of a given serious adverse event (SAE) are counted only once for that SAE. The same methodology was applied for nonserious adverse events (AE).
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | IMRT +/- Chemotherapy | Intensity modulated radiation therapy (IMRT) for all patients and chemotherapy (cisplatin and fluorouracil) for patients with stage ≥ T2b and/or N+ | 55 | 68 | 68 | 68 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Febrile neutropenia | Blood and lymphatic system disorders | CTC (2.0) |
| ||
| Hemoglobin decreased | Blood and lymphatic system disorders | CTC (2.0) |
| ||
| Packed red blood cell transfusion | Blood and lymphatic system disorders | CTC (2.0) |
| ||
| Edema NOS | Cardiac disorders | CTC (2.0) |
| ||
| Left ventricular failure | Cardiac disorders | CTC (2.0) |
| ||
| Sinus tachycardia | Cardiac disorders | CTC (2.0) |
| ||
| Supraventricular arrhythmia NOS | Cardiac disorders | CTC (2.0) |
| ||
| Ventricular arrhythmia NOS | Cardiac disorders | CTC (2.0) |
| ||
| Hearing impaired | Ear and labyrinth disorders | CTC (2.0) |
| ||
| Hearing-Other | Ear and labyrinth disorders | CTC (2.0) |
| ||
| Otitis externa (exc boil of meatus) NOS | Ear and labyrinth disorders | CTC (2.0) |
| ||
| Endocrine-Other | Endocrine disorders | CTC (2.0) |
| ||
| Hypothyroidism | Endocrine disorders | CTC (2.0) |
| ||
| Diarrhea NOS | Gastrointestinal disorders | CTC (2.0) |
| ||
| Dry mouth | Gastrointestinal disorders | CTC (2.0) | Systematic Assessment |
| |
| Dysphagia | Gastrointestinal disorders | CTC (2.0) |
| ||
| Esophageal spasm | Gastrointestinal disorders | CTC (2.0) |
| ||
| Esophagitis NOS | Gastrointestinal disorders | CTC (2.0) |
| ||
| Nausea | Gastrointestinal disorders | CTC (2.0) |
| ||
| Radiation mucositis | Gastrointestinal disorders | CTC (2.0) |
| ||
| Salivary gland disorder NOS | Gastrointestinal disorders | CTC (2.0) | Systematic Assessment |
| |
| Stomatitis | Gastrointestinal disorders | CTC (2.0) |
| ||
| Vomiting NOS | Gastrointestinal disorders | CTC (2.0) |
| ||
| Fatigue | General disorders | CTC (2.0) |
| ||
| Pain due to radiation | General disorders | CTC (2.0) |
| ||
| Pain-other | General disorders | CTC (2.0) |
| ||
| Pyrexia | General disorders | CTC (2.0) |
| ||
| Implant infection | Infections and infestations | CTC (2.0) |
| ||
| Infection NOS | Infections and infestations | CTC (2.0) |
| ||
| Infection with grade 3 or 4 neutropenia | Infections and infestations | CTC (2.0) |
| ||
| Infection with unknown ANC | Infections and infestations | CTC (2.0) |
| ||
| Infection, Other | Infections and infestations | CTC (2.0) |
| ||
| Dermatitis radiation NOS | Injury, poisoning and procedural complications | CTC (2.0) |
| ||
| Alanine aminotransferase increased | Investigations | CTC (2.0) |
| ||
| Aspartate aminotransferase increased | Investigations | CTC (2.0) |
| ||
| Blood creatinine increased | Investigations | CTC (2.0) |
| ||
| CD4 lymphocytes decreased | Investigations | CTC (2.0) |
| ||
| Inappropriate ADH secretion | Investigations | CTC (2.0) |
| ||
| Leukocytes for BMT | Investigations | CTC (2.0) |
| ||
| Leukopenia NOS | Investigations | CTC (2.0) |
| ||
| Lymphopenia | Investigations | CTC (2.0) |
| ||
| Neutropenia | Investigations | CTC (2.0) |
| ||
| Platelet count decreased | Investigations | CTC (2.0) |
| ||
| Weight decreased | Investigations | CTC (2.0) |
| ||
| Weight increased | Investigations | CTC (2.0) |
| ||
| Acidosis NOS | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Anorexia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Blood albumin decreased | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Blood magnesium decreased | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Dehydration | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hyperglycemia NOS | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hyperkalemia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hypocalcemia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hypokalemia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hyponatremia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hypophosphatemia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Joint, muscle, or bone-Other | Musculoskeletal and connective tissue disorders | CTC (2.0) |
| ||
| Tumour pain | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | CTC (2.0) |
| ||
| Headache NOS | Nervous system disorders | CTC (2.0) |
| ||
| Neurologic-Other | Nervous system disorders | CTC (2.0) |
| ||
| Peripheral motor neuropathy | Nervous system disorders | CTC (2.0) |
| ||
| Peripheral sensory neuropathy | Nervous system disorders | CTC (2.0) |
| ||
| Syncope | Nervous system disorders | CTC (2.0) |
| ||
| Anxiety NEC | Psychiatric disorders | CTC (2.0) |
| ||
| Depression NEC | Psychiatric disorders | CTC (2.0) |
| ||
| Hallucination NOS | Psychiatric disorders | CTC (2.0) |
| ||
| Renal failure NOS | Renal and urinary disorders | CTC (2.0) |
| ||
| Renal/GU-Other | Renal and urinary disorders | CTC (2.0) |
| ||
| Dyspnea NOS | Respiratory, thoracic and mediastinal disorders | CTC (2.0) |
| ||
| Hypoxia | Respiratory, thoracic and mediastinal disorders | CTC (2.0) |
| ||
| Pneumonitis NOS | Respiratory, thoracic and mediastinal disorders | CTC (2.0) |
| ||
| Pulmonary-other | Respiratory, thoracic and mediastinal disorders | CTC (2.0) |
| ||
| Erythema multiforme | Skin and subcutaneous tissue disorders | CTC (2.0) |
| ||
| Skin-Other | Skin and subcutaneous tissue disorders | CTC (2.0) |
| ||
| Hemorrhage NOS | Vascular disorders | CTC (2.0) |
| ||
| Hypotension NOS | Vascular disorders | CTC (2.0) |
| ||
| Thrombosis NOS | Vascular disorders | CTC (2.0) |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hematologic-Other | Blood and lymphatic system disorders | CTC (2.0) |
| ||
| Hemoglobin decreased | Blood and lymphatic system disorders | CTC (2.0) |
| ||
| Edema NOS | Cardiac disorders | CTC (2.0) |
| ||
| Earache | Ear and labyrinth disorders | CTC (2.0) |
| ||
| Hearing impaired | Ear and labyrinth disorders | CTC (2.0) |
| ||
| Hearing-Other | Ear and labyrinth disorders | CTC (2.0) |
| ||
| Late RT toxicity: Auditory/hearing: NOS | Ear and labyrinth disorders | RTOG/EORTC Late Tox. | Systematic Assessment |
| |
| Otitis media serous NOS | Ear and labyrinth disorders | CTC (2.0) |
| ||
| Hypothyroidism | Endocrine disorders | CTC (2.0) |
| ||
| Constipation | Gastrointestinal disorders | CTC (2.0) |
| ||
| Diarrhea NOS | Gastrointestinal disorders | CTC (2.0) |
| ||
| Dry mouth | Gastrointestinal disorders | CTC (2.0) | Systematic Assessment |
| |
| Dysphagia | Gastrointestinal disorders | CTC (2.0) |
| ||
| Esophagitis NOS | Gastrointestinal disorders | CTC (2.0) |
| ||
| GI-other | Gastrointestinal disorders | CTC (2.0) |
| ||
| Late RT toxicity: Esophagus: NOS | Gastrointestinal disorders | RTOG/EORTC Late Tox. | Systematic Assessment |
| |
| Late RT toxicity: Larynx: NOS | Gastrointestinal disorders | RTOG/EORTC Late Tox. | Systematic Assessment |
| |
| Late RT toxicity: Mucous membrane: NOS | Gastrointestinal disorders | RTOG/EORTC Late Tox. | Systematic Assessment |
| |
| Late RT toxicity: Salivary gland: NOS | Gastrointestinal disorders | RTOG/EORTC Late Tox. | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | CTC (2.0) |
| ||
| Radiation mucositis | Gastrointestinal disorders | CTC (2.0) |
| ||
| Salivary gland disorder NOS | Gastrointestinal disorders | CTC (2.0) | Systematic Assessment |
| |
| Stomatitis | Gastrointestinal disorders | CTC (2.0) |
| ||
| Vomiting NOS | Gastrointestinal disorders | CTC (2.0) |
| ||
| Fatigue | General disorders | CTC (2.0) |
| ||
| Late RT toxicity: Other: NOS | General disorders | RTOG/EORTC Late Tox. | Systematic Assessment |
| |
| Pain due to radiation | General disorders | CTC (2.0) |
| ||
| Pain-other | General disorders | CTC (2.0) |
| ||
| Pyrexia | General disorders | CTC (2.0) |
| ||
| Rigors | General disorders | CTC (2.0) |
| ||
| Infection NOS | Infections and infestations | CTC (2.0) |
| ||
| Dermatitis radiation NOS | Injury, poisoning and procedural complications | CTC (2.0) |
| ||
| Late RT toxicity: Skin (within RT field): NOS | Injury, poisoning and procedural complications | RTOG/EORTC Late Tox. | Systematic Assessment |
| |
| Late RT toxicity: Subcutaneous tissue (within RT field): NOS | Injury, poisoning and procedural complications | RTOG/EORTC Late Tox. | Systematic Assessment |
| |
| Alanine aminotransferase increased | Investigations | CTC (2.0) |
| ||
| Aspartate aminotransferase increased | Investigations | CTC (2.0) |
| ||
| Blood alkaline phosphatase NOS increased | Investigations | CTC (2.0) |
| ||
| Blood bilirubin increased | Investigations | CTC (2.0) |
| ||
| Blood creatinine increased | Investigations | CTC (2.0) |
| ||
| Gamma-glutamyltransferase increased | Investigations | CTC (2.0) |
| ||
| Leukopenia NOS | Investigations | CTC (2.0) |
| ||
| Lymphopenia | Investigations | CTC (2.0) |
| ||
| Metabolic-Other | Investigations | CTC (2.0) |
| ||
| Neutropenia | Investigations | CTC (2.0) |
| ||
| Platelet count decreased | Investigations | CTC (2.0) |
| ||
| Weight decreased | Investigations | CTC (2.0) |
| ||
| Anorexia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Blood albumin decreased | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Blood magnesium decreased | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Dehydration | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hyperglycemia NOS | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hyperkalemia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hypocalcemia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hypokalemia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hyponatremia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Hypophosphatemia | Metabolism and nutrition disorders | CTC (2.0) |
| ||
| Joint, muscle, or bone-Other | Musculoskeletal and connective tissue disorders | CTC (2.0) |
| ||
| Late RT toxicity: Bone (incl. osteonecrosis): NOS | Musculoskeletal and connective tissue disorders | RTOG/EORTC Late Tox. | Systematic Assessment |
| |
| Late RT toxicity: Joint: NOS | Musculoskeletal and connective tissue disorders | RTOG/EORTC Late Tox. | Systematic Assessment |
| |
| Dizziness (exc vertigo) | Nervous system disorders | CTC (2.0) |
| ||
| Headache NOS | Nervous system disorders | CTC (2.0) |
| ||
| Neuralgia NOS | Nervous system disorders | CTC (2.0) |
| ||
| Peripheral motor neuropathy | Nervous system disorders | CTC (2.0) |
| ||
| Peripheral sensory neuropathy | Nervous system disorders | CTC (2.0) |
| ||
| Taste disturbance | Nervous system disorders | CTC (2.0) |
| ||
| Confusion | Psychiatric disorders | CTC (2.0) |
| ||
| Insomnia NEC | Psychiatric disorders | CTC (2.0) |
| ||
| Renal/GU-Other | Renal and urinary disorders | CTC (2.0) |
| ||
| Cough | Respiratory, thoracic and mediastinal disorders | CTC (2.0) |
| ||
| Dysphonia | Respiratory, thoracic and mediastinal disorders | CTC (2.0) |
| ||
| Dyspnea NOS | Respiratory, thoracic and mediastinal disorders | CTC (2.0) |
| ||
| Epistaxis | Respiratory, thoracic and mediastinal disorders | CTC (2.0) |
| ||
| Hiccups | Respiratory, thoracic and mediastinal disorders | CTC (2.0) |
| ||
| Pulmonary-other | Respiratory, thoracic and mediastinal disorders | CTC (2.0) |
| ||
| Rhinitis allergic NOS | Respiratory, thoracic and mediastinal disorders | CTC (2.0) |
| ||
| Alopecia | Skin and subcutaneous tissue disorders | CTC (2.0) |
| ||
| Dermatitis exfoliative NOS | Skin and subcutaneous tissue disorders | CTC (2.0) |
| ||
| Erythema multiforme | Skin and subcutaneous tissue disorders | CTC (2.0) |
| ||
| Skin discoloration | Skin and subcutaneous tissue disorders | CTC (2.0) |
| ||
| Skin-Other | Skin and subcutaneous tissue disorders | CTC (2.0) |
| ||
| Toxicoderma | Skin and subcutaneous tissue disorders | CTC (2.0) |
|
PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Wendy Seiferheld | NRG Oncology | seiferheldw@nrgoncology.org |
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| D011832 | Radiation Injuries |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D014947 | Wounds and Injuries |
Not provided
Not provided
| ID | Term |
|---|---|
| D002945 | Cisplatin |
| D005472 | Fluorouracil |
| D050397 | Radiotherapy, Intensity-Modulated |
| ID | Term |
|---|---|
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017672 | Nitrogen Compounds |
| D017671 | Platinum Compounds |
| D014498 | Uracil |
| D011744 | Pyrimidinones |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D020266 | Radiotherapy, Conformal |
| D011881 | Radiotherapy, Computer-Assisted |
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
Not provided
Not provided